Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

a Wong, M.D., Associate Professor of Pediatrics and Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, who presented the data today at CNS and is one of the trial's lead investigators. "Based on the findings from this study, we believe that the safety profile of PTC124 supports continued testing in longer-term studies."

"These results add to the growing body of safety data for PTC124, which has now been evaluated in more than 150 subjects, including patients with both DMD and cystic fibrosis. The safety profile has consistently shown that PTC124 appears well tolerated," said Langdon Miller, M.D., Chief Medical Officer of PTC. "We are looking forward to presenting additional activity data from this study next week at the World Muscle Society meeting in Italy."

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children). More information regarding DMD is available through the Muscular Dystrophy Association (http://www.mdausa.org) and the Parent Project Muscular Dystrophy (http://www.parentprojectmd.org).

About PTC124

PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely halt the translation process, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease models harboring nonsense mutations. In Ph
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... Utah , Aug. 29, 2014  BC Technical, ... has acquired Polaris Medical Imaging, a leader in sales, ... This strategic acquisition allows BC Technical to continue to ... specifically within MR and CT modalities. ... service," said Mark Alvarez , president and CEO ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today announced ... dose-escalation study to evaluate the safety and tolerability of ... or Btk,as a potential treatment for patients with relapsed ... the first Btk selective inhibitor to,be tested in humans, ...
... MicroRNA-based Molecular Diagnostics to Mark Prometheus, Entry into ... and Development Funding plus Future RoyaltiesSAN DIEGO, PHILADELPHIA ... Inc., a specialty pharmaceutical and diagnostic company, and ... an innovative molecular diagnostic company, today announced the ...
Cached Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 3Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 4Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 6
(Date:8/31/2014)... 31, 2014 To make it easy ... they can trust, NutriGold is shipping complimentary samples of ... has been set up to make taking advantage of ... According to Priya Khan, Director of Research and Development ... one of our products, they are entrusting us with ...
(Date:8/31/2014)... Rockville, MD (PRWEB) August 31, 2014 ... electronic health records (EHR) software firm that focuses ... overall practice success found a congruent commitment with ... In Sports . , “We create an environment ... and effortlessly, allowing more time with patients,” says ...
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... Wine only protects against cardiovascular disease (CVD) in people ... Veritas (IVV) study presented at ESC Congress today by ... Taborsky said: "This is the first randomised trial comparing ... of atherosclerosis (1) in people at mild to moderate ... was only protective in people who exercised. Red and ...
(Date:8/30/2014)... A retrievable and repositionable transcatheter aortic valve is ... according to research presented at ESC Congress 2014 ... direct flow medical (DFM) transcatheter aortic valve has ... the potential to improve transcatheter aortic valve implantation ... , Dr Pyxaras said: "TAVI is well established ...
Breaking Medicine News(10 mins):Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:Wine only protects against CVD in people who exercise 2Health News:Retrievable transcatheter aortic valve effective and safe in real world setting 2
... Reporter , MONDAY, May 28 (HealthDay News) -- Updated ... good news for those at risk of osteoporosis, but ... other chronic diseases. While estrogen-only and estrogen-plus-progestin formulations ... for stroke and other conditions including gallbladder disease, according ...
... study suggests that aspirin and other similar painkillers may ... CANCER , a peer-reviewed journal of the American ... may be added to the benefits of these commonly ... anti-inflammatory drugs, or NSAIDs, which include aspirin, ibuprofen, and ...
... Reporter , MONDAY, May 28 (HealthDay News) -- Sensory ... increasingly used by occupational therapists to treat children with ... organization says there isn,t much evidence that such therapies ... the potential of sensory therapies -- it,s a ripe ...
... -- Picnics, parades and cookouts are as much a part ... war veterans. But, before tucking into that leafy, green ... vegetables can become contaminated with harmful pathogens that cause food ... listeria and norovirus, according to the Academy of ...
... -- Boosting students, levels of physical education improves their ... followed more than 200 schoolchildren, starting from first through ... to an intervention group that received physical education five ... such as balance and coordination. The other children were ...
... , FRIDAY, May 25 (HealthDay News) -- People ... colitis, may be at increased risk for flare-ups when ... or mountain climbing, a new study suggests. This ... involves the small intestine) or ulcerative colitis (which typically ...
Cached Medicine News:Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 2Health News:HRT Update: Therapy May Reduce Fractures, Boost Some Risks 3Health News:Commonly used painkillers may protect against skin cancer 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 2Health News:Doubt Cast on Usefulness of 'Sensory' Therapies for Autism 3Health News:Keep Food Safety in Mind This Memorial Day Weekend 2Health News:Travel to High Altitudes Tied to Crohn's, Colitis Flare-Ups 2
... Monitor (PCM) and Central Station provide an ... extends the cardiac cath or electrophysiology lab ... and/or EP procedures, providing both physiomonitoring parameters ... either standalone or on its own network. ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
... Gemini Family of infusion pumps ... a collective series of administration ... line offers a wide variety ... sets, each featuring the patented ...
Medicine Products: